Protein-protein interactions between RUNX3 and ZEB1 in chronic lung injury induced by methamphetamine abuse

Ning Bao1*, Lin Cheng2†, Yun Wang3, Zhe Peng1, Zhengkun Wang1 and Shuangquan Chen1

1Department of Anesthesiology, Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, Guangdong, China, 2Department of Pharmacy, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China, 3Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China

Methamphetamine (MA) is the most common and highly addictive substance abuse drug. Runt-related transcription factor 3 (RUNX3) and Zinc finger E-box-binding homeobox 1 (ZEB1) are associated with lung inflammation and fibrosis. However, the protein-protein interactions (PPIs) between RUNX3 and ZEB1 and its involvement in MA-induced chronic lung injury is still unclear. In this study, we evaluated lung injury using echocardiography, hematoxylin and eosin staining, and western blot analysis. The viability of alveolar epithelial cells (AECs) was assessed using cell counting kit-8. Molecular Operating Environment software, Search Tool for the Retrieval of Interacting Genes/Proteins database, co-immunoprecipitation, assay and confocal immunofluorescence assay were used to predict and identify the PPIs between RUNX3 and ZEB1. The expression of RUNX3 and ZEB1 were knockdown in AECs using siRNA. The results revealed that MA exposure increased the peak blood flow velocity of the pulmonary artery and the acceleration time of pulmonary artery blood flow. Further, exposure to MA also causes adhesion and fusion of the alveolar walls and altered AEC activity. A decrease in the expression of RUNX3 and an increase in the expression of ZEB1 and its downstream signaling molecules were observed on MA exposure. The PPIs between RUNX3 and ZEB1 were identified. Further, an increase in the protein binding rate of RUNX3-ZEB1 was observed in MA-induced lung injury. These results show interactions between RUNX3 and ZEB1. RUNX3 protects against lung injury, however, ZEB1 expression and the PPIs between ZEB1 and RUNX3 has deleterious effects on chronic lung injury induced by MA exposure. Our results provide a new therapeutic approach for the treatment of chronic lung injury due to MA exposure.

KEYWORDS
methamphetamine, protein-protein interactions, RUNX3, Zeb1, lung injury
1 Introduction

Drug abuse is a global health concern. As per analysis conducted by National Surveys on Drug Use and Health, an estimated rate of methamphetamine (MA) abuse in adults was 0.66% (Jones et al., 2020). The primary cause of MA-associated mortality is lung and heart diseases, excluding overdose and accidental death (Xiaoshan et al., 2020). MA exposure induces pulmonary edema, pneumorrhagia, pneumothorax, pulmonary artery hypertension, etc. (Kevil et al., 2019). Various proteins, such as runt-related transcription factor 3 (RUNX3), are associated with MA-induced lung toxicity. RUNX3 alters reactive oxygen species (ROS) levels in chronic lung injury due to MA exposure (Shi et al., 2020). RUNX3 belongs to the RUNX family and has a highly conserved DNA sequence which plays an important role in various biological processes, like the development of the nervous system and aging (Kulkarni et al., 2018; Mevel et al., 2019). RUNX3 interacts with the proteins in the Hippo signaling pathway and suppresses yes-associated protein-mediated epithelial-mesenchymal transition (EMT), inflammation, stemness, and metastasis of the cells (Kulkarni et al., 2018). A previous study has demonstrated the involvement of RUNX3 in the development and homeostatic maintenance of the body (Yokomizo-Nakano and Sashida, 2021). Further, an increase in RUNX3 level enhances the sensitivity to radiotherapy in lung cancer patients (Gao et al., 2021). RUNX3 suppresses apoptosis of cells in the acute lung injury caused by pancreatitis. A previous study has demonstrated that RUNX3 is essential for the EMT of cells in chronic pulmonary damage due to MA (Shi et al., 2020). However, the role of RUNX3 in chronic lung injury caused by MA exposure is still unclear.

Zinc finger E-box-binding homeobox 1 (ZEB1) is a transcription factor that induces EMT and coordinates with other transcription factors to promote metastasis, invasion, and chemoresistance in tumors (Zhang et al., 2015; Cheng et al., 2021). ZEB1 interacts with the proteins of Hippo signaling pathway to promote the development of various solid tumors (Lehmah et al., 2016). ZEB1 induces stemness and chemoresistance in cancer cells and leads to the fibrosis of cells (Zhang et al., 2015). ZEB1 overexpression in hypertrophic alveolar epithelial cells (AECs) induces the EMT of alveolar epithelial type II cells (Yao et al., 2019). However, the involvement of ZEB1 in chronic lung injury caused by MA abuse is unknown.

To check if RUNX3 and ZEB1 are correlated, we hypothesized possible protein-protein interactions (PPIs) between RUNX3 and ZEB1. PPIs play an important role in various biological processes (Li B et al., 2019). A previous report suggests that PPIs between N-cadherin and Nectin-2 form the basis of cell-cell adhesion (Duraivelan et al., 2018). The PPIs between Amyloid precursor protein and Munc18-interacting proteins induce amyloid-β formation in Alzheimer’s disease (Bartling et al., 2021). With recent development in pharmaceuticals, various novel drugs targeting PPIs are currently in the pre-clinical and clinical stages. For example, 1-benzoyl 4-phenoxypiperidines, a small molecular inhibitor, blocks the PPIs between β-catenin and B-cell lymphoma 9 (Li et al., 2021). A previous study has shown that the PPIs between B-cell lymphoma-2 and Parkin mediate mitophagy via the PTEN-induced putative kinase 1/Parkin pathway in the lipopolysaccharide-induced lung injury (Zhang Z et al., 2020). However, the PPIs between RUNX3 and ZEB1 have never been reported. Further, the involvement of PPI between RUNX3 and ZEB1 in the chronic lung injury induced by MA is still obscure.

Based on these findings, our study aimed to investigate if long-term exposure to MA can influence the functions of RUNX3 and ZEB1. Further, we investigated the interactions between RUNX3 and ZEB1 and the involvement of the interactions between RUNX3 and ZEB1 in chronic lung injury induced by long-term exposure to MA.

2 Experimental procedures

2.1 Establishment of animal models

Thirty male BALB/C mice were obtained from SPF Biotechnology Co., Ltd (license number: SCXK 2019–0010, Beijing). The mice were randomly divided into the control and the MA groups. 1 mg/kg MA (China Criminal Police University, China) was injected intraperitoneally to the mice in the 1st week. Further, the weekly dose was increased by 1 mg/kg/week and was increased to 6 mg/kg by the 6th week (Zhang Y et al., 2020). The mice in the control group were injected an equivalent of 0.9% saline intraperitoneally. The mice were weighed daily. The percentage of weight gain in each group was calculated every week as per Formula 1. After 6 weeks, the right ventricular index (RVI) was calculated using Formula 2 to evaluate the remodeling of the right ventricle due to chronic pulmonary dysfunction caused by MA exposure (Wang et al., 2020). All experimental procedures involving animals were in compliance with the China Medical University Institutional Animal Care and Use Committee (IACUC Issue No. CMU2019215).

\[
\text{Percentage of the weight gain} = \frac{\text{average of the weekly weight} - \text{average of the initial weight}}{\text{average of the initial weight}} \times 100\%
\]

\[
\text{RVI} = \frac{\text{the weight of the right heart}}{\text{the weight of the left heart} + \text{the weight of the ventricular septum}}
\]

2.2 Echocardiography

Transthoracic echocardiography was performed using a VEVO (Visualsonics 3100) system to measure the
cardiopulmonary function under chronic exposure to MA. The peak blood flow velocity of the pulmonary artery (PV), the acceleration time of pulmonary artery blood flow (PAT), and the right ventricular free wall thickness (RVWT) were measured.

Briefly, Mice were anesthetized using 1–2% isoflurane in air. To determine the RVWT, the M-mode probe was oriented to the long-axis tangent plane, which was adjacent to the breastbone and sloped towards the right shoulder of mice. The pulsed-wave doppler was used to measure PV and PAT. The pulsed-wave doppler probe was located at the long-axis in the vicinity of the breastbone. The angle of the probe was ≤ 60°, and the frequency was 24 MHz.

2.3 Hematoxylin and eosin staining

The lungs were infused with 0.9% physiological saline and were immersed in the fixative solution for 14 days. The lungs were then embedded in paraffin. The paraffin-embedded lung tissues were sectioned in 4 µm thick sections, and HE staining was performed per the manufacturer’s instruction (Solarbio Cat# G1120). To check for lung injuries, three fields on the section were randomly selected and analyzed (magnification: ×200, ×400).

2.4 Cell culture, treatment, and transfection

AECs (A549, Beijing Dingguo Changsheng Biotechnology Co., Ltd.) were cultured in Dulbecco’s Modified Eagle Medium (DMEM)F12 medium (Sevenbio, Beijing, China) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in 5% CO₂. AECs were treated with 0.1, 0.5, 1, and 5 mM MA for 12, 24, and 48 h.

The siRNA sequence used for transfection is shown in Table 1. The transfections were performed using the Lipofectamine™ 8000 Transfection Reagent (Beyotime, Cat# C0533) according to the manufacturer’s instructions. The cells were treated with 5 mM MA at the time of highest transfection efficiency for 48 h. Further, western blot analysis and CCK-8 assay were performed for subsequent analysis.

2.5 Cell counting kit-8 assay

The cells were allowed to grow until 70% confluence and then were digested with pancreatic enzymes. The cells were centrifuged, the supernatant was discarded, and the cell pellet was evenly diluted with 1 ml culture medium. The cells were evenly seeded in 96 well plates (Jet Biofil), and the cell viability was determined using the CCK-8 assay kit (APExBIO Cat# K1018) according to the manufacturer’s instructions.

2.6 Bioinformatics prediction

Search Tool for the Retrieval of Interacting Genes/Protein (STRING) database was used to generate the gene network associated with RUNX3 and ZEB1. The structure of RUNX3 was predicted by the Robetta server, and the structure of ZEB1 was predicted using the I-TASSER server. Molecular Operating Environment (MOE) software (CloudScientific Technology Co., Ltd) was used to predict the PPIs and analyze the binding sites between RUNX3 and ZEB1.

2.7 Co-Immunoprecipitation assay

The beads (Protein A/G PLUS-Agarose; Santa Cruz Biotechnology, Cat# sc-2003) were added to the AECs. The overall protein amount in each group was adjusted to the same level. The lysate was retained at 40 µL each as input. The beads were added to the rest of the lysate and were incubated at 4°C for 1 h with rotation, followed by centrifugation. The supernatant was mixed with beads and antibodies and incubated at 4°C overnight with rotation, followed by centrifugation. The supernatant was then discarded. The beads were washed, and a 2× SDS-PAGE sample loading buffer was added to the beads and boiled at 100°C for 5 min for western blot analysis. The protein binding rate of RUNX3-ZEB1 was calculated using Formula 3.

\[
\text{Protein binding rate of } \text{RUNX3} - \text{ZEB1} = \frac{\text{the protein density of RUNX3 in IP group (CON/MA)}}{\text{the protein density of RUNX3 in Input group (CON/MA)}}
\]

(3)

| Table 1 Base pairs of siRNAs for transfection. |
|-----------------------------------------------|
| Sense                                   | Antisense                                   | Source            |
| RUNX3 5′-CCCUGACCAUCACUGUGUUTT-3′          | 3′-AACACAGUGAUGUCAGGGTTT-3′                 | GENERAL BIOL      |
| ZEB1 5′-GUUCCAAGUUCUCATAUAT-3′             | 3′-TTCAAGGGGUACAAUAUAU-5′                  | GENERAL BIOL      |
| Negative control 5′-UUCUCGGAGCGUCACGTTT-3′ | 3′-ACGUGACAGCGUUCGGAGAAT-5′                | Sangon Biotech    |
2.8 Confocal immunofluorescence assay

The cells were fixed, permeabilized, and incubated with the primary antibodies at 4°C overnight. The details of the antibodies are in Table 1. The Cy3-conjugated AffiniPure goat anti-mouse IgG (H + L, Proteintech, Cat# SA00009-1) and Fluorescein (FITC)-conjugated AffiniPure goat Anti-Mouse IgG (H + L, Proteintech, Cat# SA00003-1) were used for the immunofluorescence. All the specimens were observed under the oil immersion lens of a confocal laser scanning microscope.

### Primary antibodies for western blot analysis.

| Primary antibodies | Dilution | Company   | Catalogue |
|--------------------|----------|-----------|-----------|
| CTGF               | 1: 2000  | ABclonal  | A11067    |
| Caspase-3          | 1: 2000  | ABclonal  | A11953    |
| Cleaved Caspase-3  | 1: 2000  | ABclonal  | A11953    |
| E-cadherin         | 1: 2000  | Affinity  | BF0219    |
| IL-6               | 1: 2000  | ABclonal  | A0286     |
| IL-1β              | 1: 1000  | ABclonal  | A1112     |
| ICAM1              | 1: 2000  | ABclonal  | A5597     |
| N-cadherin         | 1: 2000  | ABclonal  | A19083    |
| Vimentin           | 1: 50000 | Proteintech | 60330-1-lg |
| PCNA               | 1: 2000  | Proteintech | 10205-2-AP |
| RUNX3              | 1: 1000  | Cell Signaling Technology | 13089 |
| ZEB1               | 1: 2000  | Proteintech | 21544-1-AP |
| β-actin            | 1: 10000 | Proteintech | 66609-1-lg |

**Figure 1**

Hemodynamic analysis using transthoracic echocardiography and percentage of weight gain of mice. (A) The echocardiographic measurements for PV and PAT. (B) The PV in different groups. (C) The PAT in different groups. (D) The echocardiographic measurements for RV. (E) The echocardiographic measurements of RVWT in different groups. (F) Percentage of weight gain in the mice. N = 6. Data are expressed as mean ± standard deviation. *p < 0.05 vs. CON, **p < 0.01 vs. CON, ***p < 0.001 vs. CON. PV: Peak blood flow velocity of the pulmonary artery, PAT: the acceleration time of pulmonary artery blood flow. RVWT: Right ventricular free wall thickness, CON: The control group, MA: mice treated with methamphetamine.
2.9 Western blot analysis

The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was incubated with corresponding primary antibodies (Table 2) at 4°C overnight. On the next day, the membranes were incubated with secondary antibodies [HRP-conjugated AffiniPure Goat Anti-Rabbit IgG (H + L), Proteintech, Cat# SA00001-2; HRP-conjugated AffiniPure Goat Anti-Mouse IgG (H + L), Proteintech, Cat# SA00001-1] for 2 h at room temperature. The membranes were visualized by DNR Bio-Imaging systems, and densitometric analysis was performed using ImageJ software.

2.10 Statistical analysis

The data were expressed as mean ± standard deviation. Statistical analysis was performed using GraphPad Prism.
8.0.2. Student’s t-test, one-way analysis of variance (ANOVA), and two-way ANOVA were used for statistical comparisons. ANOVA was followed by Tukey multiple comparisons. \( p < 0.05 \) was considered statistically significant.

3 Results

3.1 Lung injury induced by chronic exposure to MA

3.1.1 Hemodynamic analysis using transthoracic echocardiography

Transthoracic echocardiography was used to evaluate cardiopulmonary function. The pulmonary arterial pressure accelerated due to chronic lung injury induced by long-term exposure to MA (Savai et al., 2014). The PV (180.073 ± 23.261 mm/s) in the MA group was significantly higher compared to the PV (93.630 ± 4.224 mm/s) in the control group (**\( p < 0.01 \) vs. CON; Figures 1A,B). As compared to the control group (35.417 ± 3.757 ms), a significant increase in the PAT (62.362 ± 7.717 ms) was observed in the MA group (**\( p < 0.01 \) vs. CON; Figures 1A,C). The RVWT (0.851 ± 0.106 mm) in the MA group was significantly thicker compared to the RVWT (0.278 ± 0.019 mm) in the control group (**\( p < 0.01 \) vs. CON; Figures 1D,E). Moreover, the percentage of weight gain in mice in the MA group was significantly slower compared to mice in the control group from the 4th week (CON: 22 ± 7.238%; MA: 14.14 ± 1.318%, *\( p < 0.05 \) vs. CON; Figures 1D,E).

3.1.2 Alveoli injury induced by MA exposure

The mice’s lungs in the MA group were inflamed and had redness compared to the lungs of mice in the control group (Figure 2A). The RV1 (0.323 ± 0.051) in the MA group was significantly higher compared to the RV1 (0.226 ± 0.003) in the control group, indicative of the right ventricular remodeling due to MA exposure-induced chronic lung injury (**\( p < 0.01 \) vs. CON; Figure 2B) (Wang et al., 2020). HE staining results reveal that the alveolar walls were thin and delicate in the control group. In the MA group, the alveolar fusion was larger, and the alveolar walls were thicker compared to the control group, as indicated by black arrows in Figures 2C,D (**\( p < 0.01 \) vs. CON; Figure 2E). In the MA group, the number of augmented pulmonary alveoli with a diameter ≥0.4 inches was more compared to the control group (**\( p < 0.05 \) vs. CON; Figure 2F).

3.1.3 AECs apoptosis induced by MA exposure

We treated AECs with 0.1, 0.5, 1 and 5 mM MA for 12, 24 and 48 h (Shi et al., 2020; Wang et al., 2020). The CCK-8 assay results revealed that the viability of AECs on MA exposure was time and dosage-dependent (**\( p < 0.05 \) vs. CON, ***\( p < 0.001 \) vs. CON, *\( p < 0.05 \) vs. 5 MA/12h; Figure 2G). To investigate if apoptosis of AECs was induced by MA exposure, the expression of apoptosis proteins like caspase-3, cleaved caspase-3 and proliferating cell nuclear antigen (PCNA) were detected by western blot analysis. In AEC treated with MA, an increase in expression of caspase-3 and cleaved caspase-3 was observed in a time- and dosage-dependent manner (**\( p < 0.05 \) vs. CON, **\( p < 0.01 \) vs. CON; Figures 2H,I). The expression of PCNA significantly decreased in the MA group compared to the control group (**\( p < 0.05 \) vs. CON; Figures 2H,I).

3.1.4 Inflammatory and fibrotic changes induced by MA exposure

An increase in expression of interleukin-1β (IL-1β) and intercellular adhesion molecule 1 (ICAM-1) was observed due to the chronic lung injury induced by MA exposure compared to the control (**\( p < 0.01 \) vs. CON, ***\( p < 0.001 \) vs. CON; Figure 3A). EMT biomarkers such as E-cadherin were significantly reduced, while the expression of N-cadherin and Vimentin were increased in the MA group (**\( p < 0.05 \) vs. CON, ***\( p < 0.01 \) vs. CON; Figure 3B) compared to the control group.

An increase in IL-1β and ICAM-1 expression in AECs was observed in a time and dosage-dependent manner (**\( p < 0.05 \) vs. CON, **\( p < 0.01 \) vs. 5 MA/12h, ***\( p < 0.001 \) vs. 5 MA/12h; *\( p < 0.05 \) vs. CON, **\( p < 0.01 \) vs. 5 MA/12h; Figures 3C,D). After treating AEC with MA, a significant decrease in the expression of E-cadherin was observed compared to the control group (**\( p < 0.05 \) vs. CON, **\( p < 0.01 \) vs. 5 MA/12h; Figures 3E,F). The expression trend of Vimentin was similar to N-cadherin (**\( p < 0.05 \) vs. CON; Figures 3E,F).

3.2 Effects of MA on RUNX3, ZEB1, and its downstream signaling molecules

RUNX3 expression decreased in the mice lungs due to MA exposure (**\( p < 0.05 \) vs. CON), while the ZEB1 expression increased (**\( p < 0.01 \) vs. CON; Figure 4A) compared to the mice control group. The expression of the downstream signaling molecules like connective tissue growth factor (CTGF) was assessed. CTGF is an indicator of fibrosis and belongs to the hippo signaling pathway. CTGF expression was increased in the lungs of mice in the MA group compared to the mice in the control group (**\( p < 0.05 \) vs. CON; Figure 4B). Interleukin-6 (IL-6) is an inflammatory cytokine and a key protein in the hippo...
signaling pathway. The expression of IL-6 was significantly increased in the lungs of mice in the MA group compared to the control group (*p < 0.05 vs. CON; Figure 4B). A significant reduction in RUNX3 expression in AECs was observed with an increase in MA dosage and exposure time (*p < 0.05 vs. CON, **p < 0.01 vs. CON, ***p < 0.001 vs. CON; Figures 4C,D). A significant increase in ZEB1 expression on MA exposure in a time and dosage-dependent manner (*p < 0.05 vs. CON, **p < 0.01 vs. CON, ***p < 0.001 vs. CON; Figures 4E,F).
3.3 Protein-protein interactions between RUNX3 and ZEB1

3.3.1 Bio-informatic prediction of interactions between RUNX3 and ZEB1

Based on the gene networks generated using the STRING database (*Homo sapiens*), the PPIs between RUNX3 and ZEB1 have not been reported (Figure 5A). The structure of RUNX3 was predicted using the Robetta server, and the structure of ZEB1 was predicted from the I-TASSER server (Figures 5B,C). The MOE software investigated the PPIs between RUNX3 and ZEB1 and the bio-informatic prediction (Figure 5D). As shown in Table 3, there were five binding sites between RUNX3 and ZEB1. These results indicate that RUNX3 interacts with ZEB1.
FIGURE 5
Protein-protein interactions (PPIs) between RUNX3 and ZEB1. (A) RUNX3-related gene network and ZEB1-related gene networks generated by STRING database. This network uses different color nodes to represent different proteins (ZFH3, BRD2, KRAS, RUNX3, CBFB, CTNNB1, SMAD4, EP300, TBX21, CDKN2A, SMAD5, TWIST1, SMAD3, SOX2, ZEB1, MYC, CDH1, EP300, SMARCA4, SIRT1, CTBP1, CTBP2). Different color lines represent different interactions at different gene levels (gene neighborhood, gene fusions, gene co-occurrence) or the protein levels (co-expression, protein homology). (B) The protein structure of RUNX3 predicted by the Robetta data bank. (C) The protein structure of ZEB1 predicted by the I-TASSER server. (D) Molecular docking of RUNX3 with ZEB1 using MOE software. MOE analysis showed the binding sites of the docking structure of (Continued)
3.3.2 Identifying interactions between RUNX3 and ZEB1

The co-IP results confirmed that ZEB1 interacted with RUNX3. On MA exposure, the protein binding rate of RUNX3-ZEB1 increased compared to the control group in AECs (**p < 0.01 vs. CON, Figure 5E).

The confocal immunofluorescence was performed to determine the cellular co-localization of RUNX3 and ZEB1. A decrease in RUNX3 expression on MA exposure and increased ZEB1 expression was observed. ZEB1 was primarily localized in the nucleus of the control group; however, in the MA group, the ZEB1 was localized both in the nucleus and the cytoplasm. RUNX3 was expressed in the cell nucleus and cytoplasm in the control and the MA groups. RUNX3 expression in cytoplasm was less in the MA group compared to the control group, while RUNX3 expression in nucleus remains the same. These results suggest a cellular co-localization of RUNX3 and ZEB1 (Figure 5F).

3.4 The interactions between RUNX3 and ZEB1 in MA-induced chronic lung injury

3.4.1 Effects of interactions between RUNX3 and ZEB1 on cell viability

siRUNX3, siZEB1, and siRUNX3+siZEB1 were successfully transfected in AEC and the transfection of siRNA was confirmed by western blots (Figure 6A). A change in the viability of AECs was observed in a time and dosage-dependent manner in different groups (Figure 6B). The viability of AECs in the siRUNX3+siZEB1 group was the highest, the viability of AECs in the siZEB1 group was higher compared to the Negative control (NC) group. The viability of AECs in the siRUNX3 group was the less compared to the NC group (Figure 6C). The CCK-8 assay results indicated that ZEB1 and the RUNX3-ZEB1 interactions reduced the viability of AECs, while RUNX3 expression enhanced the viability of AECs.

3.4.2 The role of RUNX3, ZEB1, and their PPIs in the mechanism of chronic lung injury induced by MA

A significant decrease in CTGF and IL-6 expression was observed in the cells in the siRUNX3+siZEB1+MA group (**p < 0.01 vs. NC + MA; ***p < 0.001 vs. NC + MA), whereas CTGF and IL-6 expression increased in the siRUNX3+MA group (**p < 0.001 vs. NC + MA; ***p < 0.001 vs. NC + MA; Figure 6D). The expression of CTGF was reduced in the siZEB1+MA group, and the expression of IL-6 was obviously decreased in the siZEB1+MA group (**p < 0.001 vs. NC + MA; Figure 6D). The co-IP results confirmed that ZEB1 interacted with RUNX3 and RUNX3 expression enhanced the viability of AECs, while RUNX3-ZEB1 interactions reduced the viability of AECs, and the expression of IL-6 was obviously decreased in the siZEB1+MA group (**p < 0.001 vs. NC + MA; Figure 6D).

In the siRUNX3+siZEB1+MA group, a reduction in caspase-3 expression was observed. Further, a significant decrease in the expression of cleaved caspase-3 was observed in cells in the siRUNX3+siZEB1+MA group (**p < 0.001 vs. NC + MA; Figure 6F). A significant increase in caspase-3 and cleaved caspase-3 expression was observed in cells in the siRUNX3+MA group (**p < 0.001 vs. NC + MA; p < 0.05 vs. NC + MA), whereas their expression significantly decreased in the siZEB1+MA group (**p < 0.001 vs. NC + MA; ***p < 0.001 vs. NC + MA; Figure 6D). On the contrary, the expression of PCNA increased in the cells in the siRUNX3+siZEB1+MA group and the siZEB1+MA group (**p < 0.001 vs. NC + MA; p < 0.05 vs. NC + MA), PCNA expression decreased in the siRUNX3+MA group (Figure 6E).

The expression of ICAM-1 and IL-1β was significantly reduced in the cells in the siRUNX3+siZEB1+MA and the siZEB1+MA groups (**p < 0.001 vs. NC + MA; ***p < 0.001 vs. NC + MA; p < 0.05 vs. NC + MA; ***p < 0.001 vs. NC + MA), and the expression of ICAM-1 and IL-1β significantly increased in the siRUNX3+MA group (**p < 0.001 vs. NC + MA; ***p < 0.001 vs. NC + MA; Figure 6F).
A significant reduction in E-cadherin expression was observed in the siRUNX3+siZEB1+MA and the siZEB1+MA groups (\( p < 0.01 \) vs. NC + MA; \( p < 0.001 \) vs. NC + MA); however, a significant increase in E-cadherin expression was observed in the siRUNX3+MA group (\( p < 0.001 \) vs. NC + MA; Figure 6G). The expression of N-cadherin and Vimentin was significantly reduced in the siRUNX3+siZEB1+MA group and the siZEB1+MA group (\( p < 0.001 \) vs. NC + MA; \( p < 0.01 \) vs. NC + MA; \( p < 0.001 \) vs. NC + MA).
NC + MA; \( p < 0.001 \) vs. NC + MA; \( p < 0.01 \) vs. NC + MA). Further, a significant increase in N-cadherin and Vimentin expression was observed in the siRUNX3+MA group (\( p < 0.05 \) vs. NC + MA; \( p < 0.001 \) vs. NC + MA; Figure 6G).

4 Discussion

MA is a major substance abuse drug in adults (Jones et al., 2020). MA abuse damages the organs and causes apoptosis and lesions in the respiratory system (Gu et al., 2017; Kevil et al., 2019; Wang et al., 2020). In this study, we show that MA causes alveolar injury and hemodynamic changes. MA exposure also leads to AECs apoptosis, inflammation, and fibrosis of the lungs. It also decreases RUNX3 expression and increases the expression of ZEB1 and affect the expression of their downstream signaling molecules. Our results revealed that the interactions between RUNX3-ZEB1 exist, and the protein binding rate between RUNX3 and ZEB1 increases on MA exposure.

RUNX3 and ZEB1 are two important proteins in metabolism. DNA damage stimulates the TP53 expression to inhibit RUNX3 expression in cancer (Date and Ito, 2020). MiR-301a suppresses RUNX3 expression, which accelerates the progression of lung cancer (Li X et al., 2019). In pulmonary diseases, RUNX3 induces the apoptosis of airway epithelial cells on viral infections (Gan et al., 2015). Previous studies have shown an association between RUNX3 and MA-induced EMT (Shi et al., 2011). Mounting evidence has demonstrated that ZEB1 is an important mediator of EMT, causes fibrosis, and damages various organs (Lee et al., 2018; Qian et al., 2019; Yuan et al., 2020). ZEB1, along with E-cadherin, are essential for fibrosis in AECs (Zhang X et al., 2020). In animal models, chronic exposure to MA causes an apparent change in cardiopulmonary functions and pulmonary parenchymal lesions. MA exposure suppressed RUNX3 and increased ZEB1 expression to facilitate MA-induced lung injury. Various studies have reported that CTGF and IL-6 are the downstream signaling molecules of RUNX3-ZEB1, which play an important role in promoting fibrosis and inflammation (Zhao et al., 2008; Lehmann et al., 2016; Kulkarni et al., 2018; Zhou X et al., 2019). As expected, the increase in expression of the downstream signaling molecules (CTGF, IL-6) was observed in MA-induced chronic lung injury.

Mechanisms associated with MA-induced lung injury is various. For example, MA-induced lung injury could be attributed to nuclear factor erythroid-2-related factor 2 (Nrf2)-mediated antioxidative defense (Bai et al., 2017). Interestingly, PPIs in MA-induced chronic lung injury have never been reported. However, PPIs play an important role in lung diseases. Tribble’s homolog 3/ glycogen synthase kinase-3β (TRIB3–GSK-3β) interactions promote lung fibrosis and could be used as the potential therapeutic target (Liu et al., 2021). The PPIs between Kelch-like ECH-associated protein 1 (Keap1) and Nrf2 play a critical role in acute lung injury (Wan et al., 2020). Based on this evidence, MOE software was used to predict the PPIs between RUNX3 and ZEB1. Co-IP assay and confocal immunofluorescence assay identified the interactions between RUNX3-ZEB1 in MA-induced chronic lung injury. Previous studies show that RUNX3 and ZEB1 function as transcription factors in the cell nucleus, consistent with our results (Sánchez-Tilló et al., 2011; Chen et al., 2016; Zhou W. N et al., 2019; Mevel et al., 2019; Guo et al., 2022). The co-IP results reveal an increase in the protein binding rate of RUNX3-ZEB1 on MA exposure, which indicated the increase in PPIs between RUNX3 and ZEB1 in MA-induced chronic lung injury.

RUNX3 and ZEB1 expression was knocked down in AECs to study the role of RUNX3, ZEB1, and the RUNX3-ZEB1 interactions. Inflammation, fibrosis, AECs apoptosis, and the increased expression of the downstream signals were alleviated by the knockdown of ZEB1 and the restraint of RUNX3-ZEB1 interactions in MA-induced lung injury. These pathological changes were aggravated by RUNX3 knockdown and MA exposure. RUNX3 protection against MA-induced lung injury was reduced due to its interactions with ZEB1. Further, ZEB1 expression is detrimental to MA-induced lung injury.

In this study, we explored the mechanism of MA-induced chronic lung injury from the perspective of PPIs, and confirmed that the RUNX3-ZEB1 interactions are critical in this mechanism. Recently, PPIs have been used in clinical settings. In 2017, FDA approved Venetoclax, a novel BCL-2 inhibitor targeting the PPIs between BCL-2 and other proteins in acute myeloid leukemia treatment (DiNardo et al., 2019; Guerra et al., 2019). Currently, various inhibitors targeting PPIs are under clinical trials, such as APG-1252 targeting Bcl-2/Bcl-XL (B-cell lymphoma-extra-large) interactions for anti-tumor therapy (Yi et al., 2020; Luo et al., 2021), and APG-115 targeting MDM2 (Mouse double minute 2 homolog)-p53 interactions in anti-tumor therapy (Fang et al., 2019; Fang et al., 2021). Results from this study suggest that RUNX3-ZEB1 interactions could be detrimental to MA-induced lung injury. These results demonstrated that RUNX3, ZEB1, and RUNX3-ZEB1 interactions play an important role in MA-induced chronic lung injury.

In conclusion, lung injury is caused by chronic exposure to MA. MA regulated RUNX3, ZEB1, and their downstream signaling molecules. Our results confirmed the interactions between RUNX3 and ZEB1. RUNX3-ZEB1 interactions affect AECs viability and are involved in MA-induced chronic lung injury. Therefore, blocking RUNX3-ZEB1 interactions can alleviate the MA-induced chronic lung injury, which could serve as a novel therapeutic strategy for the chronic lung injury induced by MA.
Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was reviewed and approved by China Medical University Institutional Animal Care and Use Committee (IACUC Issue No. CMU2019215).

Author contributions

Conceptualization: NB, LC, and YW; Funding acquisition: NB and YW; Data curation and formal analysis: LC, YW, ZP, ZW, and SC; Writing—original draft: NB and LC; Writing—review & editing: NB.

References

Bai, Y., Wang, Y., Liu, M., Gu, Y. H., Jiang, B., Wu, X., et al. (2017). Suppression of nuclear factor erythroid-2-related factor 2-mediated antioxidative defense in the lung injury induced by chronic exposure to methamphetamine in rats. Mol. Med. Rep. 15 (3), 3135–3142. doi:10.3892/ mmr.2017.6356

Bartling, C. R. O., Jensen, T. M. T., Henry, S. M., Colliander, A. L., Sereikaite, V., Wenzler, M., et al. (2021). Targeting the APP-mint2 protein-protein interaction with a Peptide-based inhibitor Reduces amyloid-β formation. J. Am. Chem. Soc. 143 (2), 891–901. doi:10.1021/jacs.0c10696

Chen, F., Liu, X., Bai, J., Pei, D., and Zheng, J. (2016). The emerging role of RUNX3 in cancer metastasis (Review). Oncol. Rep. 35 (3), 1227–1236. doi:10.3892/or.2015.4515

Cheng, L., Zhou, M. Y., Gu, Y. J., Chen, L., and Wang, Y. (2021). ZEB1: New advances in fibrosis and cancer. Mol. Cell. Biochem. 476 (4), 1643–1650. doi:10.1007/s11010-020-04036-7

Date, Y., and Ito, K. (2020). Oncogenic RUNX1: A Link between p53 Deficiency and MYC Dysregulation. Mol. Cells 43 (2), 176–181. doi:10.14348/molecules.2019.3285

DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arelanno, M., Becker, P. S., et al. (2019). Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. Blood 133 (1), 7–17. doi:10.1182/blood-2018-08-868752

Duraravelan, K., Basak, A. J., Ghosh, A., and Samanta, D. (2018). Molecular and structural bases of interaction between extracellular domains of nectin-2 and N-cadherin. Proteins 86 (11), 1157–1164. doi:10.1002/ppt.p25596

Fang, D. D., Tang, Q., Kong, Y., Lu, Y., Wang, T., Wang, Q., et al. (2021). MDM2 inhibitor AGP-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 7 (1), 90. doi:10.1038/s41419-021-00465-5

Fang, D. D., Tang, Q., Kong, Y., Wang, Q., Gu, J., Fang, X., et al. (2019). MDM2 inhibitor AGP-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J. Immunother. Cancer 7 (1), 327. doi:10.1186/s40425-019-0750-6

Gan, H., Hao, Q., Iddl. S., and Tang, H. (2015). Transcription factor Runx3 is induced by Influenza A Virus and double-Strand RNA and mediates airway epithelial cell apoptosis. Sci. Rep. 5, 17916. doi:10.1038/srep17916

Gao, C., Qiao, T., Yuan, S., and Zhaoy, X. (2021). The Preliminary study for Postoperative radiotherapy survival associated with RUNX3 and TLR9 expression in lung cancer. Cancer Manag. Res. 13, 4497–4507. doi:10.2147/cmr.s305452

Gu, Y. H., Wang, Y., Bai, Y., Liu, M., and Wang, H. L. (2017). Endoplasmic reticulum stress and apoptosis via PERK-eIF2α-CHOP signaling in the methamphetamine-induced chronic pulmonary injury. Environ. Toxicol. Pharmacol. 49, 194–201. doi:10.1016/j.etap.2017.01.003

Guerra, V. A., DiNardo, C., and Konopleva, M. (2019). Venetoclax-based therapies for acute myeloid leukemia. Best. Pract. Res. Clin. Haematol. 32 (2), 15–32. doi:10.1016/j.beha.2019.05.008

Gao, Y., Lu, X., Chen, Y., Clark, G., Trent, J., Cuatrecasas, M., et al. (2022). Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity. Cell Rep. 41 (1), 111452. doi:10.1016/j.celrep.2022.111452

Jones, C. M., Compton, W. M., and Mustajab, D. (2020). Patterns and characteristics of methamphetamine Use Among adults - United States, 2015-2018. MMWR. Morb. Mortal. Wkly. Rep. 69 (12), 317–323. doi:10.15585/mmwr.mm6912a1

Kevil, C. G., Goeders, N. E., Woolard, M. D., Bhuuay, M. S., Dominic, P., Kolluru, G. K., et al. (2019). Methamphetamine Use and Cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 39 (9), 1739–1746. doi:10.1161/ATvbaha.119.312461

Kulkarni, M., Tan, T. Z., Syed Sulaiman, N. B., Lama, J. M., Bansal, P., Cui, J., et al. (2018). RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9 (18), 14175–14192. doi:10.18632/oncotarget.24419

Luo, F., Lu, F. T., Qui, M. Z., Zhou, T., Ma, W. J., Luo, M., et al. (2021). Gemicitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis. 12 (8), 772. doi:10.1038/s41419-021-04042-7

Lee, J. G., Jung, E., and Heur, M. (2018). Fibroblast growth factor 2 induces proliferation and fibrosis via SNAI1-mediated activation of CDK2 and ZEB1 in corneal endothelium. J. Biol. Chem. 293 (10), 3758–3769. doi:10.1074/jbc.RA117.000295

Lehmann, W., Mrossmann, D., Kleemann, M., Mock, K., Messinger, C., Brummer, T., et al. (2016). ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498. doi:10.1038/ncomms10498

Li, B., Rong, D., and Wang, Y. (2019). Targeting protein-protein interaction with Covalent small-molecule inhibitors. Curr. Top. Med. Chem. 19 (21), 1872–1876. doi:10.2174/156802661966619111163410

Li, X., Zhong, M., Wang, J., Wang, L., Lin, Z., Cao, Z., et al. (2019). mib-301a promotes lung tumorgensis by suppressing Runx3. Mol. Cancer 18 (1), 99. doi:10.1186/s12943-019-1024-0

Funding

This work is supported by Natural Science Foundation of Liaoning Province (No. 2020-MS-323 and No. 2022-MS-224).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Li, Z., Zhang, M., Teuscher, K. B., and Ji, H. (2021). Discovery of 1-benzoyl-4-phenoxy-piperidines as small molecule inhibitors of the β-catenin/B-cell lymphoma 9 protein-protein interaction. J. Med. Chem. 64 (15), 11195–11218. doi:10.1021/acs.jmedchem.1c00396

Liu, S., Lv, X., Wei, X., Liu, C., Li, Q., Min, J., et al. (2021). TRIB3–GSK-3β interaction promotes lung fibrosis and serves as a potential therapeutic target. Acta Pharm. Sin. B 11 (10), 3105–3119. doi:10.1016/j.apsb.2021.06.017

Mevel, R., Draper, J. E., Lie, A. L. M., Kouskoff, V., and Lacaud, G. (2019). RUNX transcription factors: Orchestrators of development. Dev. Camb. Engle. 146 (17), dev148296. doi:10.1242/dev.148296

Qian, W., Cai, X., Qian, Q., Peng, W., Yu, J., Zhang, X., et al. (2019). IncRNA ZEB1–A51 promotes pulmonary fibrosis through ZEB1-mediated epithelial-mesenchymal transition by competitively binding miR-141-3p. Cell Death Dis. 10 (2), 129. doi:10.1038/s41419-019-1339-1

Sánchez-Tilló, E., Siles, L., de Barrios, O., Cuarteras, M., Vaquero, E. C., Castells, A., et al. (2011). Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am. J. Cancer Res. 1 (7), 897–912.

Savai, R., Al-Tamari, H. M., Sedding, D., Kojonazarov, B., Muecke, C., Teske, R., et al. (2014). Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat. Med. 20 (11), 1289–1300. doi:10.1038/nm.3695

Shi, L., Liu, B. Y., Wang, X., Zhu, M. J., Chen, L., Zhou, M. Y., et al. (2020). RUNX3-dependent oxidative epithelial–to–mesenchymal transition in methamphetamine-induced chronic lung injury. Cell Stress Chaperones 25 (5), 793–802. doi:10.1007/s12192-020-01133-w

Wan, J., Lin, S., Huang, X., Li, Q., Zeng, L., and Du, S. (2020). ZF01, a small molecule inhibitor of the Kelch-like ECH-associated protein 1–nuclear factor erythroid 2-related factor 2 (Keap1–Nrf2) protein–protein interaction, Reduces the toxicity in the retina of Balb/c mice. Cytom. Aucul. Toxicol. 39 (2), 83–88. doi:10.1002/jctb.2727

Wang, X., Liu, M., Zhu, M. J., Shi, L., Liu, L., Zhao, Y. L., et al. (2020). Resveratrol protects the integrity of alveolar epithelial barrier via SIRT1/PTEN/p-Akt pathway in methamphetamine-induced chronic lung injury. Cell Prolif. 53 (3), e12773. doi:10.1111/cpr.12773

Xiaoshan, T., Junjie, Y., Wenqeng, W., Yunong, Z., Japing, L., Shanshan, L., et al. (2020). Immunotherapy for treating methamphetamine, heroin and cocaine use disorders. Drug Discov. Today 25 (3), 610–619. doi:10.1016/j.drudis.2019.07.009

Yao, L., Conforti, F., Hill, C., Bell, J., Drawater, L., Li, J., et al. (2019). Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death Differ. 26 (5), 943–957. doi:10.1038/s41418-018-0175-7

Yi, H., Qiu, M. Z., Yuan, L., Lan, Q., Pan, W., Zhou, S., et al. (2020). Bcl-2/Bcl-xL inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 9 (12), 4197–4206. doi:10.1002/cam4.3090

Yokemizo-Nakano, T., and Sashida, G. (2021). Two faces of RUNX3 in myeloid transformation. Exp. Hematol. 97, 14–20. doi:10.1016/j.exphem.2021.02.005

Yuan, X., Pan, J., Wen, L., Gong, B., Li, J., Gao, H., et al. (2020). MiR-590–3p regulates proliferation, migration and collagen synthesis of cardiac fibroblast by targeting ZEB1. J. Cell. Mol. Med. 24 (1), 227–237. doi:10.1111/jcmm.14704

Zhang, P., Sun, Y., and Ma, L. (2015). ZEB1: At the crossroads of epithelial–mesenchymal transition, metastasis and therapy resistance. Cell cycleGeorg. Tex. 14 (4), 481–487. doi:10.1080/15384101.2015.1006048

Zhang, X., Zou, Y., Liu, C., Yao, L., Conforti, F., Hill, C., Bell, J., Drawater, L., Li, J., et al. (2020). Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells. Mol. Immunol. 125, 15–22. doi:10.1016/j.molimm.2020.06.013

Zhang, Y., Li, Q., Guan, S., and Li, H. (2020). Methamphetamine causes acute toxicity in the retina of Balb/c mice. Cytom. Aucul. Toxicol. 39 (2), 83–88. doi:10.1002/jctb.2727

Zhang, Z., Chen, Z., Liu, R., Liang, Q., Peng, Z., Yin, S., et al. (2020). Bcl-2 proteins regulate mitophagy in lipopolysaccharide-induced acute lung injury via PINK1/Parkin signaling pathway. Oxid. Med. Cell. Longev. 2020, 6579696. doi:10.1155/2020/6579696

Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., et al. (2008). TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22 (14), 1962–1971. doi:10.1101/gad.166408

Zhou, W. N., Du, Y. F., Zheng, Y., Zhang, W., Wu, Y. N., Song, X. M., et al. (2019). Inactivation of RUNX3 protein expression in tongue squamous cell carcinoma and its association with clinicopathological characteristics. Mol. Med. Rep. 20 (11), 11218. doi:10.1186/s12288-020-09570-w

.quo